News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,267 Results
Type
Article (47208)
Company Profile (296)
Press Release (679762)
Multimedia
Podcasts (87)
Webinars (15)
Section
Business (209425)
Career Advice (2193)
Deals (36072)
Drug Delivery (115)
Drug Development (82471)
Employer Resources (191)
FDA (16429)
Job Trends (15285)
News (353026)
Policy (33331)
Tag
Academia (2747)
Academic (2)
Accelerated approval (9)
Adcomms (25)
Allergies (97)
Alliances (51148)
ALS (112)
Alzheimer's disease (1485)
Antibody-drug conjugate (ADC) (162)
Approvals (16419)
Artificial intelligence (335)
Autoimmune disease (29)
Automation (18)
Bankruptcy (367)
Best Places to Work (11830)
BIOSECURE Act (20)
Biosimilars (122)
Biotechnology (199)
Bladder cancer (94)
Brain cancer (34)
Breast cancer (367)
Cancer (2894)
Cardiovascular disease (215)
Career advice (1842)
Career pathing (33)
CAR-T (194)
CDC (37)
Cell therapy (520)
Cervical cancer (23)
Clinical research (67585)
Collaboration (1049)
Company closure (3)
Compensation (681)
Complete response letters (24)
COVID-19 (2707)
CRISPR (59)
C-suite (332)
Cystic fibrosis (112)
Data (2992)
Decentralized trials (2)
Denatured (34)
Depression (61)
Diabetes (349)
Diagnostics (6575)
Digital health (23)
Diversity (10)
Diversity, equity & inclusion (48)
Drug discovery (141)
Drug pricing (131)
Drug shortages (29)
Duchenne muscular dystrophy (127)
Earnings (88321)
Editorial (43)
Employer branding (25)
Employer resources (163)
Events (117305)
Executive appointments (870)
FDA (18085)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (961)
Gene editing (135)
Generative AI (25)
Gene therapy (389)
GLP-1 (827)
Government (4662)
Grass and pollen (4)
Guidances (181)
Healthcare (19224)
Huntington's disease (32)
IgA nephropathy (41)
Immunology and inflammation (155)
Immuno-oncology (9)
Indications (39)
Infectious disease (2884)
Inflammatory bowel disease (152)
Inflation Reduction Act (13)
Influenza (62)
Intellectual property (121)
Interviews (346)
IPO (16804)
IRA (47)
Job creations (3850)
Job search strategy (1572)
Kidney cancer (13)
Labor market (55)
Layoffs (516)
Leadership (20)
Legal (8091)
Liver cancer (80)
Lung cancer (409)
Lymphoma (209)
Machine learning (11)
Management (62)
Manufacturing (396)
MASH (92)
Medical device (13613)
Medtech (13618)
Mergers & acquisitions (19982)
Metabolic disorders (873)
Multiple sclerosis (99)
NASH (22)
Neurodegenerative disease (121)
Neuropsychiatric disorders (33)
Neuroscience (2177)
NextGen: Class of 2025 (6723)
Non-profit (4660)
Now hiring (48)
Obesity (447)
Opinion (237)
Ovarian cancer (102)
Pain (108)
Pancreatic cancer (121)
Parkinson's disease (190)
Partnered (22)
Patents (299)
Patient recruitment (163)
Peanut (52)
People (59703)
Pharmaceutical (72)
Pharmacy benefit managers (21)
Phase I (21063)
Phase II (29755)
Phase III (22145)
Pipeline (1630)
Policy (208)
Postmarket research (2643)
Preclinical (9195)
Press Release (72)
Prostate cancer (140)
Psychedelics (38)
Radiopharmaceuticals (259)
Rare diseases (466)
Real estate (6241)
Recruiting (73)
Regulatory (23070)
Reports (59)
Research institute (2482)
Resumes & cover letters (375)
Rett syndrome (9)
RNA editing (9)
RSV (51)
Schizophrenia (90)
Series A (165)
Series B (111)
Service/supplier (14)
Sickle cell disease (63)
Special edition (20)
Spinal muscular atrophy (151)
Sponsored (33)
Startups (3791)
State (2)
Stomach cancer (15)
Supply chain (76)
Tariffs (57)
The Weekly (51)
Vaccines (811)
Venture capital (55)
Weight loss (274)
Women's health (47)
Worklife (18)
Date
Last 7 days (373)
Last 30 days (1807)
Last 365 days (31673)
2025 (16929)
2024 (35959)
2023 (40865)
2022 (51927)
2021 (56503)
2020 (54901)
2019 (47648)
2018 (35942)
2017 (33099)
2016 (32678)
2015 (38782)
2014 (32378)
2013 (27541)
2012 (29798)
2011 (30537)
2010 (29032)
Location
Africa (798)
Alabama (63)
Alaska (7)
Arizona (252)
Arkansas (14)
Asia (39906)
Australia (6553)
California (7486)
Canada (2363)
China (680)
Colorado (330)
Connecticut (318)
Delaware (193)
Europe (86802)
Florida (1120)
Georgia (257)
Hawaii (2)
Idaho (60)
Illinois (653)
India (28)
Indiana (369)
Iowa (17)
Japan (229)
Kansas (110)
Kentucky (31)
Louisiana (15)
Maine (64)
Maryland (1033)
Massachusetts (5600)
Michigan (263)
Minnesota (467)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (68)
New Jersey (2096)
New Mexico (30)
New York (2114)
North Carolina (1120)
North Dakota (10)
Northern California (3288)
Ohio (238)
Oklahoma (16)
Oregon (34)
Pennsylvania (1619)
Puerto Rico (17)
Rhode Island (36)
South America (1177)
South Carolina (34)
South Dakota (1)
Southern California (2788)
Tennessee (126)
Texas (1131)
United States (27911)
Utah (224)
Virginia (184)
Washington D.C. (77)
Washington State (637)
West Virginia (4)
Wisconsin (79)
727,267 Results for "gilead sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
The Global Fund to Fight AIDS, Tuberculosis and Malaria will work with Gilead and other private backers to ensure the HIV preventive Yeztugo, approved last month by the FDA, is available in low- and middle-income countries, concurrent with high-income nations.
July 10, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused five clinical trials. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline.
June 10, 2025
·
3 min read
·
Annalee Armstrong
Regulatory
FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More
Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir.
June 2, 2025
·
6 min read
·
Tristan Manalac
Infectious disease
Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails
Analysts believe that Gilead’s new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.
July 2, 2025
·
4 min read
·
Nick Paul Taylor
Collaboration
Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.
June 25, 2025
·
2 min read
·
Tristan Manalac
Earnings
Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space
Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch remain on track.
April 25, 2025
·
3 min read
·
Tristan Manalac
Cell therapy
Gilead Gears Up To Challenge J&J in $20B Multiple Myeloma CAR -T Market
J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at least as good efficacy.
June 4, 2025
·
5 min read
·
Nick Paul Taylor
Press Releases
Gilead Sciences to Present at Upcoming Investor Conferences
April 29, 2025
·
1 min read
Manufacturing
Gilead Pumps $11B More Into US Manufacturing, Hopes To Add 3,000 Jobs
Gilead will construct three new facilities in the U.S., while upgrading three others. The company claims the investment will produce "$43 billion in value.”
May 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences Announces First Quarter 2025 Financial Results
April 25, 2025
·
19 min read
1 of 72,727
Next
